바디텍메드

206640KOSDAQ

60.5 / 100

Reference Date: 2026-10-23

Financial Score30.0 / 40

News Sentiment12.5 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit metrics are weak. Declined 9.9% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Bodytekmed operates two business segments: immune diagnostic cartridges and diagnostic devices. It supplies a wide range of products, including CRP, PCT, and D-Dimer cartridges, as well as ichroma and AFIAS series diagnostic equipment, to global markets. Following the COVID-19 pandemic, the company expanded its antigen testing products and continues to launch high-value items like ST2 and TDM diagnostic kits. The AFIAS series, featuring automated functionality, is expected to drive sales growth due to enhanced user convenience.

Number of Employees

601people

Average Salary

49.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

7.75Industry Average 15.006.5Point

Lower than industry avg (good)

PBR

0.76Industry Average 1.205.5Point

Lower than industry avg (good)

ROE

10.22Industry Average 8.004.0Point

In line with industry avg

Debt Ratio

5.76Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲10.1% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲1.3% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 12.5% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 8,460Won52-week high 13,97052-week low 8,460

1-month return1.0Point

1m -9.90% (falling)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0